Nav: Home

National hospital system uses enterprise approach for assessing bleeding risks

May 04, 2016

Orlando, Fla. - The largest risk-directed study by a national hospital system demonstrates a 40 percent decline in bleeding events for percutaneous coronary intervention (PCI) patients and a significant reduction in pharmacy costs. This quality improvement project (QIP) study was presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions in Orlando, Fla.

PCI opens narrow or blocked coronary arteries. While it is a common non-surgical procedure, PCI-related bleeding can result in substantial morbidity and mortality. The QIP study aimed to reduce these bleeding events by using the National Cardiovascular Data Registry (NCDR) bleeding risk calculator and applying it to evidence-based bleeding avoidance strategies, including bivalirudin use.

"We found that some centers were using bivalirudin 100 percent of the time and others were not using it at all," said Jerome E. Granato, MD, vice president and medical director, National Cardiovascular Service Line at Catholic Health Initiatives, and the study's lead author. "Our goal was to determine the most appropriate time to use bivalirudin, which is why the bleeding risk calculator was so vital."

The two-year study (2013-2015) involved 8,713 PCI procedures from 21 hospitals, in 11 states, with more than 200 operators. The baseline Q1 2013 risk-adjusted bleeding event rate was 6.3 percent. Researchers used the bleeding risk calculator (Q2 2014) during the intra-procedural "time-out" and, based on the score, divided patients into high, intermediate or low bleeding risk groups. Depending on the risk assessment, access site and anticoagulant use, other interventions were used at the discretion of the operator.

Over the two-year period, incidence of bleeding decreased by 40 percent (6.3 percent to 3.78 percent). In addition, the cost of bleeding complications -- typically about $8,000 per patient -- was reduced by approximately $1 million for the entire hospital system.

Further, data showed that when physicians conducted the bleeding risk assessment before the procedure, they not only changed the use of the drug, they also adjusted their approach, going through the wrist instead of the groin with high-risk patients.

Researchers monitored compliance by recording patients who received bivalirudin, their risk calculator scores and the percentage who fell into each risk category. That information was relayed back to the hospitals and resulted in greater adherence to the process.

"Our results showed that in a very large patient population and an expansive health system, we were able to change behaviors that resulted in better patient care and significant financial savings," noted Dr. Granato. "We believe this process could easily be adopted by other health systems."
-end-
The authors reported no disclosures. Catholic Health Initiatives has received an unrestricted educational grant from the Medicines Company.

Dr. Granato presented "Risk Directed Interventions in Percutaneous Coronary Intervention (PCI): An Enterprise Approach for Reducing Bleeding Events" on Wednesday, May 4, 2016 at 1:45 pm ET.

For more information about the SCAI 2016 Scientific Sessions, visit http://www. SCAI.org/SCAI2016.



About SCAI


The Society for Cardiovascular Angiography and Interventions is a 4,500-member professional organization representing invasive and interventional cardiologists in approximately 70 nations. SCAI's mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's public education program, Seconds Count, offers comprehensive information about cardiovascular disease. For more information about SCAI and Seconds Count, visit http://www.SCAI.org or http://www.SecondsCount.org. Follow @SCAI on Twitter for the latest heart health news.

Society for Cardiovascular Angiography and Interventions

Related Bivalirudin Articles:

Radial, femoral access for PCI found equal in terms of survival
Doctors can use either an artery in the arm (the radial approach) or in the groin (the femoral approach) to safely perform percutaneous coronary intervention (PCI) on patients presenting with a heart attack, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.
Use of bivalirudin for anticoagulation in interventional cardiovascular procedures
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp.
CVIA special issue on special issue on current issues in cath labs
The journal Cardiovascular Innovations and Applications (CVIA) has just published a new issue, Volume 3 Issue 2.
Long-term antiplatelet monotherapy after stenting is safe but does not improve outcomes
Munich, Germany -- Aug. 27, 2018: Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.
ESC Guidelines on ST-segment elevation myocardial infarction published today
European Society of Cardiology (ESC) Guidelines on the management of acute myocardial infarction in patients with ST-segment elevation are published online today in European Heart Journal,1 and on the ESC website.
Meta-analysis evaluates the effect of post-primary PCI Bivalirudin I
A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivalirudin doses on net adverse clinical events (NACEs) and mortality.
No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study today in JACC: Cardiovascular Interventions.
Analysis looks at role type of valve plays in patient outcomes post-TAVR
Results from 'Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
Results from 'Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.
Two differing medications used during heart procedure are both safe and effective, study finds
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study.
More Bivalirudin News and Bivalirudin Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.